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Abstract
Background: Dehydroepinadrosterone (DHEA) supplementation improves pregnancy chances in
women with diminished ovarian reserve (DOR), by possibly reducing aneuploidy. Since a large
majority of spontaneous miscarriages are associated with aneuploidy, one can speculate that DHEA
supplementation may also reduce miscarriage rates.
Methods: We retroactively compared, utilizing two independent statistical models, miscarriage
rates in 73 DHEA supplemented pregnancies at two independent North American infertility
centers, age-stratified, to miscarriages reported in a national U.S. in vitro fertilization (IVF) data
base.
Results: After DHEA supplementation the miscarriage rate at both centers was 15.1% (15.0% and
15.2%, respectively). For DHEA supplementation Mantel-Hänszel common odds ratio (and 95%
confidence interval), stratified by age, was significantly lower, relative to odds of miscarriage in the
general IVF control population [0.49 (0.25-0.94; p = 0.04)]. Miscarriage rates after DHEA were
significantly lower at all ages but most pronounced above age 35 years.
Discussion: Since DOR patients in the literature are reported to experience significantly higher
miscarriage rates than average IVF patients, the here observed reduction in miscarriages after
DHEA supplementation exceeds, however, all expectations. Miscarriage rates after DHEA not only
were lower than in an average national IVF population but were comparable to rates reported in
normally fertile populations. Low miscarriage rates, comparable to those of normal fertile women,
are statistically impossible to achieve in DOR patients without assumption of a DHEA effect on
embryo ploidy. Beyond further investigations in infertile populations, these data, therefore, also
suggest the investigations of pre-conception DHEA supplementation in normal fertile populations
above age 35 years.
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Background
Casson et al. were first to suggest that dehydroepiandros-
terone (DHEA) supplementation may improve selected
aspects of ovarian function in women with diminished
ovarian reserve [1]. Because they reported only rather
small benefits from a short term supplementation proto-
col, their observation failed to attract follow up. This,
however, changed when a woman of advanced reproduc-
tive age, after self medication with DHEA, experienced
surprising gains in ovarian function [2]. That experience
led to a series of studies, investigating DHEA supplemen-
tation in infertile women with significant degrees of
diminished ovarian reserve.
Those studies suggested that DHEA supplementation
improves response to ovarian stimulation with gonado-
tropins by increasing oocyte yield and embryo numbers
[2,3]. Explaining the rather small benefits initially
observed by Casson et al after only short-term use [1],
DHEA effects increase over time, reaching peaks after
approximately four to five months of supplementation
[2,4]. DHEA, however, also increases oocyte and embryo
quality [3,4], spontaneous pregnancy rates in prognosti-
cally otherwise highly unfavorable patients on no further
active treatments [4], pregnancy rates with in vitro fertili-
zation (IVF) [4], time to pregnancy and cumulative preg-
nancy rates [4].
Why DHEA would positively affect ovarian function
parameters and pregnancy chances in women with dimin-
ished ovarian reserve is still unknown. Casson and col-
leagues suggested that the effect may be insulin-like
growth factors (IGF-1) - mediated [5]. Because DHEA
effects peak at four to five months, a time period similar
to the complete follicular recruitment cycle, we have spec-
ulated about a DHEA effect on follicular recruitment, pos-
sibly mediated via suppressive effects on apoptosis [3,4].
Following a small pilot study, of insufficient statistical
power, we also noted the possibility that DHEA may
reduce aneuploidy in embryos [6].
Since approximately 80 percent of spontaneous preg-
nancy loss is the consequence of chromosomal abnormal-
ities [7], reduced aneuploidy should also reduce
miscarriage rates. As women get older, and ovarian func-
tion progressively declines, miscarriage rates rise because
of increasing aneuploidy [8,9]. If DHEA, indeed, were to
beneficially affect ploidy, DHEA supplementation should,
as an additional benefit in older women with severely
diminished ovarian reserve, therefore, result in reduced
miscarriage rates.
Since women with diminished ovarian reserve produce
only small oocyte and embryo numbers with IVF [6,9],
preimplantation genetic diagnosis (PGD) in association
with IVF is only rarely indicated, and, indeed, may be det-
rimental [10]. To accumulate direct embryo ploidy data in
such patients is, therefore, difficult. Seeking alternatives,
we were attracted by the fact that spontaneous miscarriage
rates to such a large degree reflect aneuploidy rates. This
study, therefore, presents pregnancy outcomes after
DHEA supplementation from two independent North
American fertility centers and compares those with age-
specific national USA outcome data after IVF.
Methods
DHEA supplementation
After approval by the center's Institutional Review Board,
the Center for Human Reproduction (CHR) in New York
City has been utilizing DHEA supplementation in women
with diminished ovarian reserve since 2004. Based on
reported clinical experiences [1-4], the indications for
such supplementation have changed over the years: In ini-
tial stages, only older women, above age 42, were supple-
mented and only if they had failed at least one IVF cycle
and less than 4 oocytes had been retrieved in confirma-
tion of ovarian resistance to stimulation. By mid-2005,
indications were expanded to all women above age 40
with evidence of ovarian resistance and a history of one
failed prior IVF cycle. By early 2006 indications were fur-
ther expanded to women under age 40 if they demon-
strated elevated baseline follicle stimulating hormone
(FSH) levels above 10 mIU/ml and had shown ovarian
resistance in at least one failed IVF cycle. By mid-2006
FSH baseline criteria were changed from absolute FSH ele-
vations to elevations in age-specific FSH levels [11]. All
women above age 40 have been offered routine supple-
mentation since January 2007, while younger women,
under age 40, are continuing to be only selectively supple-
mented if demonstrating elevated age-specific baseline
follicle stimulating hormone (FSH) levels and, as previ-
ously reported, inappropriately low oocyte yield in at least
one IVF cycle [11].
DHEA supplementation in all patients involves oral, phar-
maceutical grade micronized medication at a dosage of 25
mg, three times daily (TID). Only morbidly obese women
receive an increased daily dosage of 100 mg and no such
women were involved in this study. This supplementation
dosage was chosen since it represented the amount of
medication the index patient used [2] after reading the
report by Casson et al. [1]. Limited patient volume and
funding sources have prevented dose response studies and
25 mg DHEA TID daily has, therefore, remained the only
standard treatment dosage. Patients receive at least two
months of DHEA supplementation prior to oocyte
retrieval, unless they conceive spontaneously during that
time period [4]. This minimum pretreatment period is
based on the recognition that at two months pregnancy
curves between DHEA pretreated and control patients sta-Reproductive Biology and Endocrinology 2009, 7:108 http://www.rbej.com/content/7/1/108
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tistically diverge [4]. DHEA is maintained until preg-
nancy, and is discontinued with second positive
pregnancy test.
Collaboration between centers
The utilization of DHEA at the Toronto-based center was
independently initiated, after that center's medical direc-
tor (E.R.) at a lecture (by N.G.) learned about the New
York center's DHEA experience. Toronto's data accumula-
tion was unknown to the New York center until in Decem-
ber of 2007, unsolicited, a detailed electronic record of
Toronto's DHEA experience was forwarded to New York
with a request for combined analysis. The Canadian data
were sequestered to the New York center's confidential
research data base, which is restricted to one computer.
Confidentiality and anonymity of submitted records was,
therefore, maintained.
Control population
This study reports on miscarriage rates, at both fertility
centers, independently established under DHEA supple-
mentation, and compares these rates, age-stratified, to
miscarriage rates reported in a national USA IVF outcome
data base, which involves unselected infertility patients
[12]. While study populations at the New York and
Toronto centers, thus, involve women with significantly
DOR, the national control data reflect only a rather small
percentage of women with this primary diagnosis.
DOR patients have in the past resisted prospective rand-
omization. Two registered prospectively randomized, pla-
cebo controlled trials, one in new York City and a second
in Europe, had to be abandoned for lack of enrollments
(Gleicher N and Barad DH, Unpublished data, 2006 and
2007). In the absence of such prospectively controlled
studies, the question arose how to establish statistically
valid controls for observed miscarriage rates: A control
population should involve infertile women under treat-
ment. It also should have maximal size, vary in age distri-
bution (to facilitate age stratification) and be all
encompassing (to avoid selection biases). Since here pre-
sented DHEA data were generated in North America, a
USA-based data base, fulfilling all of these criteria, was
chosen [12].
Definitions
The literature does not offer a unified definition of DOR.
Our center now defines all women above age 40 years to
suffer from DOR. In women under age 40 the diagnosis is
only reached if age-specific ovarian function parameters
so indicate [11].
Definitions of clinical pregnancy and of miscarriage fol-
low the reporting requirements of this national data base,
defining clinical pregnancy, as confirmed by ultrasound
[12].
Since patients at both study centers, as a prerequisite to
DHEA supplementation, had to suffer from DOR, their
expectation of pregnancy success is very limited [13]. Even
considering a higher conception rate in such patients after
supplementation with DHEA, [2-4] conceptions will
occur in only a small minority of DHEA supplemented
cycles. The here reported number of consecutive pregnan-
cies, therefore, represents a range of approximately 450 to
570 initiated DHEA treatment cycles.
Statistics
Miscarriage rates of DHEA supplemented patients were
statistically compared with national IVF outcomes,
reported annually under federal mandate by the Centers
for Disease Control and Prevention, U.S. Department of
Health and Human Services. The data utilized as controls
for this study reflect 2004 United States IVF statistics [12],
report cycle numbers, pregnancy percentages and live
birth percentages, stratified for age. These detailed
national data allowed calculation of number of clinical
pregnancies and number of live births for each age group,
since neither is offered in the original data set. We then
subtracted live births from pregnancies, to derive number
of failed pregnancies (i.e., all failed pregnancies were for
purpose of this study considered miscarriages) overall,
and in each age category. Counts of pregnancies and mis-
carriages were then entered into a series of two by two
tables, stratified by age, and using the cross tabulation
module of SPSS 15.00.
Pregnancy and miscarriage rates at both fertility centers
were pooled after confirmation of homogeneity of vari-
ance. Common odds ratios of the pooled miscarriage rates
among age stratified pregnant patients were compared
between the pooled centers and 2004 national rates, uti-
lizing the Mantel-Hänszel common odds ratio (tests for
homogeneity of the odds ratio across layers were not sig-
nificant, meeting assumption for use of this test) and
using dichotomous exposure (DHEA versus controls) and
dichotomous outcomes (live births versus spontaneous
miscarriages), stratified by five age categories.
A secondary statistical analysis of the data was performed,
by recalculating for all five investigated age groups (<35,
35-37, 38-40, 40-42 and >42 years) expected miscarriage
rates for both patient groups, equalized for size. Both sta-
tistical analyses are presented in sequence and were per-
formed using SPSS Windows, standard version 15.0.
Institutional Review Board
The investigation of DHEA in women with DOR has been
repeatedly approved by the center's Institutional Review
Board. Since the here reported study only involved the
evaluation of (electronic) medical records, and main-
tained their confidentiality, the here presented study,
based on a patient consent signed at time of initial regis-Reproductive Biology and Endocrinology 2009, 7:108 http://www.rbej.com/content/7/1/108
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tration, did not require further IRB approval. A confirma-
tory written statement from the chairman of the IRB is
available upon request.
Results and Discussion
New York reported 40 and Toronto 33 DHEA pregnancies,
for a combined DHEA pregnancy experience of 73 preg-
nancies. Among those pregnancies, New York registered
six and Toronto five miscarriages, for clinical miscarriage
rates of 15.0% and 15.2%, respectively, and a combined
miscarriage rate of 11/73 (15.1%). In comparison, the
total 2004 miscarriage rate in the national USA registry
was 17.6%. The odds ratio and 95% confidence interval
(CI), stratified for age, that a woman would miscarry was,
thus, statistically significantly lower after DHEA supple-
mentation [OR 0.49 (0.25 - 0.94; p = 0.04), suggesting a
reduction in miscarriage risk of approximately 50 percent
(data not shown; Mantel-Hänszel, distributed as Chi-
square with one degree of freedom, 4.285; p = 0.038).
When expected miscarriage rates were compared in both
patient groups, equalized for number of patients, women
after DHEA supplementation demonstrated even more
significant reductions in miscarriage rate (p < 0.0001) sug-
gesting an almost 80% reduction in miscarriage risk (data
not shown; Mantel-Haenszel, distributed as Chi-square
with one degree of freedom, 12.482; p < 0.0001).
Differences between DHEA treated patients and the
national IVF data became even more obvious after age-
stratification. Table 1 and Figure 1 summarize age-specific
rates in numerical and graphic formats: Miscarriage rates
at all ages were lower in DHEA patients than in the 2004
national IVF data. Those differences were, however, only
after age 35 years pronounced.
Here reported data, after DHEA supplementation, dem-
onstrate in women with DOR significantly lower miscar-
riage rates than in a standard IVF control population, - a
finding particularly pronounced above age 35 years. This
by itself remarkable observation is further enhanced by
the well recognized and reported excessive miscarriage
risk of women with DOR. Levi et al, for example, reported
that women with DOR experience miscarriage rates far in
excess of standard IVF patients with normal ovarian
reserve: 57.1 percent under age 35; 63.5 percent between
ages 35 and 40 and as high as 90 percent above age 40
years [13].
That study patients in the here reported study suffered
from DOR is best documented by them receiving DHEA
supplementation. Under our center's DHEA protocols,
except for women above age 40 years, DHEA supplemen-
tation is offered only to women who have failed at least
one prior IVF cycle with retrieval of less than four oocytes
and, therefore, have been designated resistant to ovarian
stimulation. Moreover, younger women receive DHEA
supplementation only if they also demonstrate elevated
age-specific FSH levels [11]. Finally, DHEA supplementa-
tion is voluntary, allowing for the assumption that more
Comparison of miscarriage rates at all ages between DHEA  supplemented infertility patients and 2004 national U.S. IVF  outcome data Figure 1
Comparison of miscarriage rates at all ages between 
DHEA supplemented infertility patients and 2004 
national U.S. IVF outcome data.
Figure 1
Table 1: Age-stratified pregnancy and miscarriage rates
Age (years)
<35 35-37 38-40 41-42 >42
DHEA
Pregnancies
NY 10 5 6 10 9
TO 7 10 13 0 3
Miscarriages
N Y 10023
T O 11300
Misc. Rate (%)
NY 10.0 0.0 0.0 20.0 33.3
TO 14.3 10.0 23.1 - 0.0
TOTAL 11.8 6.7 15.8 20.0 25.0
(± 95% CI) (15.0) (13.0) (16.0) (25.0) (25.0)
NATIONAL
Misc. Rate (%) 14.0 17.1 23.1 36.6 50.1
(± 95% CI) (1.0) (1.0) (1.0) (2.0) (5.0)
Decrease in Misc. Rate
with DHEA (%) -15.7 -60.8 -31.6 -45.3 -50.1
Miscarriage rates after DHEA supplementation, stratified for age, 
were lower at all ages [OR 0.49 (0.25-0.94; p = 0.04)]. The decrease 
in miscarriage rate was, however, especially apparent above age 35 
years.
NY - Center for Human Reproduction, New York;
TO - Toronto West Fertility Associates, Toronto, CanadaReproductive Biology and Endocrinology 2009, 7:108 http://www.rbej.com/content/7/1/108
Page 5 of 7
(page number not for citation purposes)
severely compromised patients, with poorer past IVF expe-
riences, will more likely choose supplementation.
In contrast, USA IVF outcome data only in a minority rep-
resent women with diminished ovarian reserve [12]. As
Levi et al. demonstrated [13], control populations, there-
fore, should demonstrate significantly lower miscarriage
rates than our study patients. The finding that women on
DHEA supplementation demonstrate in all age groups,
but especially above age 35, significantly lower miscar-
riages than the much more favorable national IVF popula-
tion is, therefore, noteworthy.
That this difference is less obvious under age 35, only
strengthens the validity of the here utilized controls.
Indeed, the larger degree of reduction in miscarriage rates
in older women should not surprise: Aneuploidy rates
increase with age [7-9], and age 35 is generally considered
the cut off, when invasive prenatal genetic screening
becomes indicated [14]. Assuming a beneficial effect of
DHEA on aneuploidy rates, a larger effect after age 35
should, therefore, be expected.
Levi et al. reported in women with diminished ovarian
reserve above age 40 an approximately 90% miscarriage
rate [13]. Since older women produce fewer embryos, the
relative benefits from decreases in aneuploidy rate on
number of euploid embryos, transferred into the uterus,
will increase with advancing female age [15].
Aneuploidy is, however, even in young women a frequent
finding [15,16]. In women with diminished ovarian
reserve Levi et al. reported an almost 60 percent miscar-
riage rate under age 35 years [13]. As women physiologi-
cally age, the prevalence of aneuploidy continues to
increases, reaching close to 90 percent in the mid- 40s
[13,17]. Premature ovarian aging, however, does not pre-
maturely enhance aneuploidy rates, and instead main-
tains expected age-specific aneuploidy rates [18]. Though
demonstrating features of ovarian aging, affected women,
therefore, still experience age-appropriate implantation -
and pregnancy rates. Because of decreased oocyte and
embryo yields, they, however, do demonstrate reduced
cumulative pregnancy rates [19,20]. Even though signifi-
cantly affected by prematurely diminished ovarian
reserve, a smaller benefit from DHEA under age 35 in our
study population should, therefore, not surprise.
By demonstrating in a very high risk population for spon-
taneous pregnancy loss a statistical association between
DHEA supplementation and decreased miscarriage rates,
this study does not prove causation. The study, therefore,
does not prove that DHEA decreases miscarriage or ane-
upoidy rates in human embryos. The here reported data,
however, offer enough circumstantial evidence to suggest
that DHEA may, indeed, exert both of these effects and,
therefore, warrant further investigations. A suggestion of
improved euploidy after DHEA supplementation was,
after all, also observed in human embryos [6].
Another obvious weakness of the study is the absence of a
prospectively established direct control group. Such stud-
ies, as our previously noted experience documents, are,
however, practically impossible to conduct. Women with
severely diminished ovarian reserve often have very lim-
ited time to conceive. They, therefore, understandably are
resistant to any form of randomization that involves pla-
cebo. Because women with DOR, in the absence of DHEA
supplementation, rarely conceive [4], expectations for
prospectively randomized DHEA studies are not very
favorable. Indeed, two attempts at such studies, one in the
United States and the other in Europe, had to be aban-
doned because of insufficient enrollment of women will-
ing to be randomized to placebo (Gleicher N and Barad
DH; Unpublished data, 2006 and 2007).
Our center's miscarriage rates in women with DOR, prior
to introduction of DHEA supplementation, were, likely,
higher than the national rate seen in the here utilized con-
trol population [15]. The program's pregnancy rates in
these women were then only in low single digits [4]. The
gradual introduction of DHEA supplementation between
2004 and 2007 progressively improved pregnancy rates at
our center [21]. Increasing pregnancy numbers anecdo-
tally suggested a concomitant decline in miscarriage rates.
This observation, in turn, lead to the previously noted
investigation of aneuploidy rates in embryos after DHEA
supplementation, which, though statistically underpow-
ered, was supportive of a beneficial DHEA effect on ploidy
[6].
The New York center's pregnancy and miscarriage data,
alone, were, however, not large enough to allow for statis-
tically valid conclusions about factual miscarriage rates.
Such conclusions became possible, once the independ-
ently collected Toronto data became available, and statis-
tical analysis demonstrated that the two data sets could be
unified. At this point the question arose how to control
the two centers' miscarriage experiences. A statistical com-
parison to a large and unselected, national data set
appeared appropriate.
While such a comparison cannot replace the gold stand-
ard of study design, - the prospectively randomized and
placebo controlled study, the here presented data, never-
theless, offer valuable new information. We in this study
used carefully vetted statistical methodologies, which are
appropriate for the kind of comparisons offered. Moreo-
ver, we even performed a second statistical analysis, based
on a different statistical model, which suggested an evenReproductive Biology and Endocrinology 2009, 7:108 http://www.rbej.com/content/7/1/108
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bigger beneficial statistical effect of DHEA supplementa-
tion, increasing the potential benefit from an approxi-
mately 50 percent to an approximately 80 percent
reduction in miscarriage risk.
Whether the benefit of DHEA supplementation is, indeed,
50 or 80 percent can as of this moment not be ascertained
with certainty, but also should not matter. What seems of
importance is the observation that DHEA supplementa-
tion, at least in women with DOR, who characteristically
demonstrate abnormally high miscarriage rates [13],
appears to significantly reduce the risk for spontaneous
pregnancy loss.
Our here presented data may, at least partially, also help
to explain why DHEA supplementation increases egg and
embryo quality [1-4], improves pregnancy rates and
speeds up time to conception [4]. Egg and embryo quality
is, of course, at least partially a reflection of ploidy. More
euploid embryos will lead to more pregnancies [22], thus
shortening time to conception.
It is important to note that DHEA supplementation, as
described, appears safe and results in only minor side
effects. Since DHEA is a mild androgen but is converted
into testosterone (and estradiol), it should not surprise
that observed mild side effects, such as oily skin, mild
acne vulgaris and hair loss, are mostly androgenic in
nature.
Embryo selection and improving embryo ploidy have
been the rationale for attempts at improving pregnancy
rates and reducing miscarriage rates via preimplantation
genetic screening (PGS) [16,17,22], a concept recently
seriously questioned [23,24]. Here presented data suggest
that DHEA supplementation may result in more cost
effective improvements in ploidy without laboratory
intervention.
Though infertile women with normal ovarian reserve
experience significantly lower miscarriage rates than DOR
patients [13], they still experience higher miscarriage rates
than average populations [25]. Here reported miscarriage
rates in DHEA treated DOR patients are, therefore,
remarkably low and practically identical to those reported
for general populations [26,27]. Caution should, never-
theless, be exercised in concluding that observed DHEA
effect can automatically be extrapolated to normal, fertile
populations, though such a possibility deserves further
investigation. If confirmed, one could perceive DHEA as a
routine preconception supplement, akin to prenatal vita-
mins, even in women with no fertility problems.
Conclusion
Based on the hypothesis that major disturbances in chro-
mosome alignment on the meiotic spindle of oocytes
(i.e., congression failure) result from complex interplay of
signals, regulating folliculogenesis (increasing the risk of
non-disjunction errors), Hodges et al. suggested that it
may be possible to develop prophylactic treatments which
can reduce the risk of age-related aneuploidy [28]. This
study suggests that DHEA may, indeed, be a first such
drug.
Should efficacy of DHEA supplementation be proven not
only in infertile patients but also in general populations,
the potential significance on public health could be con-
siderable and by far exceed the more imminent utilization
of DHEA in fertility practice.
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